

A provider's guide to helping patients save on Atomoxetine (Strattera). Covers generics, coupons, patient assistance, and cost conversations.
When patients can't afford their medication, they don't take it. For Atomoxetine — a medication that requires 4 to 6 weeks of consistent daily use before reaching full therapeutic effect — cost-driven non-adherence is particularly damaging. A patient who skips doses or abandons treatment during the critical ramp-up period may conclude the medication doesn't work, when the real problem was affordability.
As a provider, you're in a unique position to intervene. A brief cost conversation at the point of prescribing can make the difference between a patient who fills their prescription and one who doesn't. This guide gives you the tools and resources to help.
Understanding the price landscape helps you anticipate which patients will face barriers:
The spread is enormous. A patient at one pharmacy may pay $27 with a GoodRx coupon while another pays $400+ at a different pharmacy without one — for the exact same generic medication. Many patients don't know these tools exist.
Generic Atomoxetine is covered by most commercial plans and Medicare Part D. However, common barriers include:
If a patient's insurance requires step therapy, documenting the clinical rationale for Atomoxetine as a first-line choice (e.g., substance abuse history, anxiety comorbidity, patient preference for non-controlled medication) in the prior authorization can help overcome this barrier.
Since generic Atomoxetine is widely available, Eli Lilly does not currently offer a manufacturer savings card for Strattera. However, one important resource remains:
The Lilly Cares Foundation (lillycares.com) provides Lilly medications — including brand Strattera — at no cost to qualifying patients. Eligibility is based on financial need and lack of prescription drug coverage.
This program is most relevant for:
Application requires provider involvement (prescriber signature). Keep copies of the form in your office for easy access.
For most patients, the fastest path to savings on generic Atomoxetine is a prescription discount card. These are free, don't require insurance, and can be used at most major pharmacies:
Important note for patients with insurance: Coupon cards sometimes beat insurance copays, especially for patients with high-deductible plans. Encourage patients to compare their insurance copay with the coupon price and use whichever is lower.
Always prescribe generic Atomoxetine unless there's a specific clinical reason for brand Strattera. Generic is bioequivalent and costs a fraction of the brand price. There are multiple generic manufacturers, so availability is generally good.
If cost remains a barrier even with generic Atomoxetine and discount cards, consider whether a therapeutic alternative might be more affordable or better covered by the patient's insurance:
For a patient-facing comparison of these options, you can share our alternatives guide.
Integrating cost discussions into prescribing doesn't have to be time-consuming. Here are practical strategies:
The price of generic Atomoxetine ranges from $27 to over $400 for the same medication at different pharmacies. That's not a medical problem — it's an information problem. By spending 30 seconds directing patients to a discount card or assistance program, you can dramatically improve adherence and outcomes.
The resources exist. Your patients just need to know about them. For a patient-friendly version of this information, share our guide: How to Save Money on Atomoxetine.
For tools to help your patients find Atomoxetine in stock at nearby pharmacies, visit Medfinder for Providers.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.